|
After Billions Are Made, Risks from Asthma Drug Emerge
CounterPunch World sales of Merck's blockbuster asthma drug, Singulair, were about $5 billion a year until last year when its patent expired in the United States. But the drug also has a darkening cloud over it. The Australian medicine watchdog has received 58 … |
View full post on asthma – Google News